141 related articles for article (PubMed ID: 36370473)
41. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
Bruchertseifer F; Kellerbauer A; Malmbeck R; Morgenstern A
J Labelled Comp Radiopharm; 2019 Sep; 62(11):794-802. PubMed ID: 31369165
[TBL] [Abstract][Full Text] [Related]
42. The use of radioisotopes for palliation of metastatic bone pain.
Gkialas I; Iordanidou L; Galanakis I; Giannopoulos S
J BUON; 2008; 13(2):177-83. PubMed ID: 18555462
[TBL] [Abstract][Full Text] [Related]
43. Targeted alpha therapy for cancer.
Allen BJ; Raja C; Rizvi S; Li Y; Tsui W; Zhang D; Song E; Qu CF; Kearsley J; Graham P; Thompson J
Phys Med Biol; 2004 Aug; 49(16):3703-12. PubMed ID: 15446799
[TBL] [Abstract][Full Text] [Related]
44. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J
Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760
[TBL] [Abstract][Full Text] [Related]
45. The treatment of solid tumors by alpha emitters released from (224)Ra-loaded sources-internal dosimetry analysis.
Arazi L; Cooks T; Schmidt M; Keisari Y; Kelson I
Phys Med Biol; 2010 Feb; 55(4):1203-18. PubMed ID: 20124656
[TBL] [Abstract][Full Text] [Related]
46. Targeted α-particle therapy of bone metastases in prostate cancer.
Jadvar H; Quinn DI
Clin Nucl Med; 2013 Dec; 38(12):966-71. PubMed ID: 24212441
[TBL] [Abstract][Full Text] [Related]
47. Leveraging the power of non-radium radionuclide treatments in bone metastases.
Thapa P; Basu S
Q J Nucl Med Mol Imaging; 2019 Jun; 63(2):159-169. PubMed ID: 31271269
[TBL] [Abstract][Full Text] [Related]
48. Alpha-Particle Therapy for Multifocal Osteosarcoma: A Hypothesis.
Baranowska-Kortylewicz J; Sharp JG; McGuire TR; Joshi S; Coulter DW
Cancer Biother Radiopharm; 2020 Aug; 35(6):418-424. PubMed ID: 32073902
[TBL] [Abstract][Full Text] [Related]
49. Comparative studies on the potential use of
Zakaly HMH; Mostafa MYA; Deryabina D; Zhukovsky M
Int J Radiat Biol; 2020 Jun; 96(6):779-789. PubMed ID: 32043915
[No Abstract] [Full Text] [Related]
50. Targeted Alpha Therapy: Current Clinical Applications.
Guerra Liberal FDC; O'Sullivan JM; McMahon SJ; Prise KM
Cancer Biother Radiopharm; 2020 Aug; 35(6):404-417. PubMed ID: 32552031
[TBL] [Abstract][Full Text] [Related]
51. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Ryan CJ; Saylor PJ; Everly JJ; Sartor O
Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
[TBL] [Abstract][Full Text] [Related]
52. The calculation of stopping power and range for radium, thorium and uranium using new electronic potential energy function.
Usta M
Appl Radiat Isot; 2019 Oct; 152():193-199. PubMed ID: 31382112
[TBL] [Abstract][Full Text] [Related]
53. Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients.
Bellmunt J
Eur Urol; 2013 Feb; 63(2):198-200. PubMed ID: 23062225
[No Abstract] [Full Text] [Related]
54. Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.
Dauer LT; Williamson MJ; Humm J; O'Donoghue J; Ghani R; Awadallah R; Carrasquillo J; Pandit-Taskar N; Aksnes AK; Biggin C; Reinton V; Morris M; St Germain J
Health Phys; 2014 Apr; 106(4):494-504. PubMed ID: 24562070
[TBL] [Abstract][Full Text] [Related]
55. Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.
Jadvar H
Cancer Biother Radiopharm; 2020 Sep; 35(7):475-484. PubMed ID: 32202923
[TBL] [Abstract][Full Text] [Related]
56. Biodistribution and Multicompartment Pharmacokinetic Analysis of a Targeted α Particle Therapy.
Tichacek CJ; Tafreshi NK; Kil H; Engelman RW; Doligalski ML; Budzevich MM; Gage KL; McLaughlin ML; Wadas TJ; Silva A; Moros E; Morse DL
Mol Pharm; 2020 Nov; 17(11):4180-4188. PubMed ID: 32960613
[TBL] [Abstract][Full Text] [Related]
57. Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.
Abou DS; Ulmert D; Doucet M; Hobbs RF; Riddle RC; Thorek DL
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26683407
[TBL] [Abstract][Full Text] [Related]
58. An alpha edge?
Silberstein EB
Oncology (Williston Park); 2012 Apr; 26(4):345, 348. PubMed ID: 22655527
[No Abstract] [Full Text] [Related]
59. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
60. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.
Subbiah V; Anderson PM; Kairemo K; Hess K; Huh WW; Ravi V; Daw NC; Somaiah N; Ludwig JA; Benjamin RS; Chawla S; Hong DS; Meric-Bernstam F; Ravizzini G; Kleinerman E; Macapinlac H; Rohren E
Clin Cancer Res; 2019 Jul; 25(13):3802-3810. PubMed ID: 30733229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
